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Abstract
Objectives. Recent whole-genome and candidate gene association studies in RA have identified a
number of single nucleotide polymorphisms (SNPs) that predispose to disease with moderate risk. It
remains poorly understood how recently identified genetic factors may contribute to RA severity. We
therefore sought to investigate the role of recently identified RA susceptibility SNP markers in predicting
erosive outcome in patients with recent-onset inflammatory polyarthritis (IP).
Methods. DNA and X-ray data were available for 1049 patients who were registered between 1990 and
2003 with the Norfolk Arthritis Register (NOAR); a primary care-based inception cohort of patients with
recent-onset IP. Demographic and clinical data were recorded at inclusion, and at yearly assessments
thereafter. Patients were genotyped for 18 SNP markers. The presence of serum anti citrullinated peptide
antibodies (ACPAs) was assessed in samples collected at inclusion to the NOAR. The association of
serological and genetic markers with poor radiological (Larsen) score at Years 1 and 5, and erosions at
Years 1 and 5 was investigated.
Results. Baseline ACPA positivity was associated with erosive disease and higher radiological damage.
SNP markers within the TRAF1/C5 locus were associated with erosive disease at Year 1 [rs2900180: odds
ratio (OR) 1.53 (95% CI 1.14, 2.05)] and Year 5 [rs2900180: OR 1.47 (95% CI 1.07, 2.02)]. None of the SNP
markers tested was associated with Larsen score.
Conclusion. Our results are in keeping with a previous report and suggest that the TRAF1/C5 region is
associated with risk of development of radiological erosions in IP/RA patients. The finding requires
replication in other large data sets.
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Introduction
Increasingly, physicians would like to identify which
patients presenting with inflammatory joint disease are
likely to develop severe disease before they satisfy ACR
classification criteria for RA, so that appropriate treatment
can be introduced before irreversible damage occurs. The
importance of antibodies directed against citrullinated
peptide antibodies (ACPAs) in this regard has been
increasingly appreciated in recent years [1–5]. For exam-
ple, we have reported previously that, in the Norfolk
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Arthritis Register (NOAR), an inception cohort of patients
with inflammatory polyarthritis (IP), only 45% of whom
satisfied ACR classification criteria for RA at baseline,
the presence of ACPA was strongly associated with the
development of erosions by 5 years [1]. However, ACPA
do not perfectly correlate with severe outcome. For exam-
ple, in the same study, there were a significant minority of
patients who did not have these antibodies at baseline but
developed severe disease, as assessed by radiological
erosions [1]. Hence, the identification of markers that
would refine the accuracy of ACPA in predicting disease
severity would be an important clinical advance.
Genetic factors play an important role in determining
development of persistent and destructive IP, and are
estimated to account for 50–60% of disease susceptibil-
ity. In patients of European ancestry, the strongest genetic
susceptibility effects are conferred by the HLA-DRB1
locus on chromosome 6 [6] [the shared epitope (SE)]
and the protein tyrosine phosphatase 22 (PTPN22) gene
on chromosome 1p13 [7]. In terms of disease outcome,
the HLA-DRB1 locus is associated with the development
of radiological erosions [8]. The functional susceptibility
single nucleotide polymorphism (SNP) within PTPN22
does not appear to associate with disease outcome in
persistent IP or RA [9].
Recent whole-genome and candidate gene disease
association studies have identified further non-HLA RA
susceptibility loci (i.e. 6q23, TRAF1/C5, STAT4, IL2RB,
KIF5A, PRKCQ, IL2_IL21, CD226, CCL21, CD40, CTLA4,
IL2RA, AFF3 and IL7R), defined by SNP markers that
associate with susceptibility with low-to-moderate risk
[10–19]. What is less clearly understood, however, is the
role of these SNP susceptibility markers in determining
disease outcome as measured by the presence of radio-
graphic erosions in patients with persistent IP.
Using a large primary care-based inception cohort of
patients with recent-onset IP, we examined the relation-
ship of baseline prognostic factors, including ACPA
positivity, carriage of HLA-SE risk alleles and the newly
confirmed RA SNP susceptibility markers, with radiologi-
cal erosion at 1 and 5 years of follow-up.
Methods
Subjects
The NOAR is a primary care-based inception cohort of
patients with recent-onset IP. Further details of this regis-
ter are described elsewhere [20]. In brief, patients aged
516 years at symptom onset, who had synovitis of two or
more joints, lasting54 weeks, and whose symptom onset
was after 1 January 1990, are recruited from general prac-
titioners and rheumatologists in the catchment area, for-
merly covered by the Norwich Health Authority (UK).
Ethical approval was obtained from the Norwich District
Health Authority Research Ethics Committee, and all par-
ticipants gave informed consent. Clinical and demo-
graphic data were collected by a research nurse via a
structured interview and clinical examination shortly after
registration (baseline). In addition, DNA and serum
samples were collected to permit genetic and serological
studies. Excluded from the study were patients who
received a clinical diagnosis other than RA, IP, PsA or
post-viral arthritis at baseline assessment or subsequent
follow-up.
Data collection
Demographic data included age, date of symptom onset
and gender. Clinical data included information on DMARD
and steroid therapy. X-rays of the hands and feet were
taken at 1 and/or 2 years in patients who satisfied ACR
criteria for RA (or would satisfy ACR criteria for RA should
evidence of erosions be detected), and at 5 years unse-
lectively. They were read independently by two observers
using the Larsen method [21] with a third observer arbi-
trating in case of disagreement. ACPAs were measured
using the CCP2 detection kit (positivity55 U/ml; Axis-
Shield, Cambridgeshire, UK) using baseline serum sam-
ples. The presence of HLA-SE copy number (0, 1 or 2
copies) was detected using a semi-automated reverse
hybridization method (Dynal Biotech, Wirral, UK).
Genotyping
Eighteen SNPs were selected for genotyping using
Sequenom MassArray technology according to the manu-
facturer’s instructions, using iPLEX chemistry (Sequenom,
Hamburg, Germany). The SNPs were markers associated
with RA susceptibility in cohorts tested by our group and
others and consisted of: rs1160542 (AFF3), rs2812378
(CCL21), rs763361 (CD226), rs4810485 (CD40),
rs3087243 and rs231775 (CTLA4), rs6822844 (IL2/IL21),
rs2104286 (IL2RA), rs743777 (IL2RB), rs6897932 (IL7R),
rs1678542 (KIF5A), rs4750316 (PRKCQ), rs7574865
(STAT4), rs13207033, rs5029937 and rs6920220 (6q23),
rs10760130 and rs2900180 (TRAF1/C5). Only those
SNPs with a genotype success rate of >90% were
included in the analysis.
Statistical analysis
Univariate analysis. The IP patients with X-ray data at
5 years (5-year IP cohort) were unselected and are most
representative of those in whom the identification of risk
factors to inform decisions regarding treatment would be
most helpful. First, therefore, logistic regression was used
to investigate the association of potential prognostic mar-
kers with erosive disease, as a binary outcome, by the
5-year follow-up. Patients were defined as having erosive
disease if they had a Larsen score52 in at least one joint
of the hands or feet. Secondly, in order to determine
whether markers were associated with the severity or
extent of erosive disease in those with erosions, negative
binomial regression models were used to investigate the
association between potential prognostic markers and
Larsen scores by Year 5 in patients with confirmed erosive
disease. Negative binomial regression models were
employed to model count data, in preference to Poisson
regression, to account for any over-dispersion of variance.
The subgroup of patients who satisfied the ACR criteria
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for RA by the fifth anniversary follow-up (5-year RA sub-
group) was analysed separately [22].
The subgroup of patients with X-ray data at 1 year
(1-year IP cohort) are not an unselected group. X-rays
were only undertaken at Year 1 if the subjects had met
or could meet ACR classification criteria for RA. Hence,
they represent a more severe subset of all patients pre-
senting with IP and it was hypothesized that markers with
evidence of association with erosions in the IP group as a
whole may show stronger evidence for association in this
more severe subgroup. Therefore, the same analysis was
undertaken investigating markers for association with ero-
sions and Larsen score by Year 1 in the 1-year IP cohort
as detailed above for the 5-year IP cohort. All the analyses
were repeated after adjustment for treatment (i.e. ever
treated with DMARDs/steroids following symptom onset)
to determine whether this materially altered the findings.
Multivariate analysis. ACPA positivity is strongly predic-
tive of radiographic erosions in RA [1–5]; therefore, SNP
markers were investigated in the context of ACPA
status. Multivariate logistic regression models were used
to investigate the role of SNP markers in predicting
erosions at Years 5 and 1 following adjustment for
ACPA status, and to investigate SNP markers in the
stratum of patients who were either positive or negative
for these antibodies. In addition, SNP markers were
investigated in the context of HLA-SE allele carriage
(i.e. carriage of at least one SE allele). All statistical
analyses were conducted using Stata version 9 (2005.
Stata Statistical Software: Release 9; Stata Corp.,
College Station, TX, USA).
Results
Study population characteristics
Genotyping data were available from 2611 IP patients, of
which 2538 passed genotyping quality control (97% suc-
cess). Radiological data were available for 1378 patients.
One thousand and forty-nine patients had both genotype
and X-ray data and remained available to study. Six
hundred and sixty-three IP patients had X-ray data avail-
able for Year 5 (5-year IP cohort) of whom 489 patients
satisfied ACR criteria for RA (5-year RA subgroup), while
761 IP patients had X-ray data available for Year 1 (1-year
IP cohort). Three hundred and seventy-five patients were
X-rayed at both time points—of 234 patients who were
initially non-erosive (by Year 1), 80 (34%) developed ero-
sive disease by Year 5 (all 375 patients satisfied ACR
criteria for RA by 5-year follow-up and were included in
the 5-year analysis). The characteristics of these patients
are summarized in Table 1.
Radiological erosions by Year 5
We have previously reported that the presence of ACPA is
associated with the development of erosions [1]. In this
extended data set, we again found that ACPA positivity
was strongly associated with erosive disease in the 5-year
IP cohort as a whole and in the 5-year RA subgroup
(Table 2; for complete table of results, see supplementary
table 1, available as supplementary data at Rheumatology
Online). As expected, due to the strong correlation
between ACPA and HLA-SE, carriage of HLA-SE alleles
also strongly associated with erosive disease at 5 years
(Table 2).
Only 2 of the 18 SNPs tested showed a trend towards
association with the presence of erosions by Year 5. Both
SNPs map to the TRAF1/C5 locus and the minor allele of
both markers is associated with susceptibility to RA in
multiple populations [23]. The SNP marker rs2900180
(TRAF1/C5) was associated, by carriage of the minor
allele, with erosive disease by the 5-year follow-up in
both the 5-year IP cohort as a whole and the RA subset
(Table 2). The other SNP, rs10760130, showed a trend
towards association but this did not achieve statistical
significance (Table 2). Moderate linkage disequilibrium
exists between rs10760130 and rs2900180, R2= 0.67
[24]. Adjustments for DMARD/steroid treatment did not
materially alter these findings (analysis not shown).
Although ACPA status, carriage of HLA-SE alleles and
carriage of the minor allele of the SNP markers were asso-
ciated with the presence of erosions by 5 years, only
TABLE 1 Summary of cohort characteristics
Cohort characteristics
5-year IP cohort
(n=663)
5-year RA cohort
(n=489)
1-year RA cohort
(n=761)
Age at symptom onset, median (IQR), years 53 (42–63) 55 (44–65) 57 (46–68)
Delay from onset to registration, median (IQR), months 5.2 (2.4–11.0) 5.3 (2.5–11.0) 5.4 (2.6–12.0)
Female, n (%) 448 (68) 333 (68) 520 (68)
HAQ score baseline, median (IQR) 0.75 (0.25–1.38) 0.88 (0.25–1.5) 1 (0.5–1.6)
Larsen score Year 1, median (IQR) – – – – 5 (0, 15)
Erosive disease Year 1, n (%) – – – – 365 (48)
Larsen score Year 5, median (IQR) 5 (0–21) 10 (1–29) – –
Erosive disease Year 5, n (%) 291 (44) 272 (56) – –
Anti-CCP positive, n (%) 170 (29) 163 (38) 269 (39)
Satisfy ACR criteria for RA, n (%) 489 (74) – – 761 (100)
CCP: cyclic citrullinated peptide.
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ACPA positivity and HLA-SE carriage were associated
with higher Larsen score by Year 5 in both the 5-year IP
cohort as a whole and in the 5-year RA subgroup (Table
3). There was no association of the SNP markers
rs2900180 and rs10760130 with Larsen score by Year 5
(Table 3).
Radiological erosions by Year 1
As expected, ACPA and HLA-SE status also strongly
associated with the development of erosions in the
1-year IP cohort (Table 2; for complete table of results,
see supplementary table 1, available as supplementary
data at Rheumatology Online). Both the rs2900180 and
rs10760130 TRAF1/C5 SNPs were associated, by car-
riage of the minor allele, with erosive disease at Year 1
(Table 2). The odds ratios (ORs) conferred by carriage of
the minor allele were higher in the 1-year RA group com-
pared with the 5-year IP cohort as a whole—in keeping
with our hypothesis that the 1-year IP cohort represents a
more severe group (Table 2). However, this is unlikely to
TABLE 2 Association between prognostic markers and erosive disease
Marker
5-year IP
cohort obs.
Erosions at
Year 5 OR
(95% CI)
5-year RA
subgroup obs.
Erosions at
Year 5 OR
(95% CI)
1year RA
cohort obs.
Erosions at
Year 1 OR
(95% CI)
Anti-CCP 577 424 682
Positive 170 9.12 (5.96, 14.00);
P = 5.1e29
163 6.80 (4.26, 10.85);
P = 2.2e18
269 5.59 (4.00, 7.83);
P = 9.2e26
HLA-SE 603 455 693
Carriage 368 2.17 (1.55, 3.05);
P = 5.7e06
284 2.59 (1.76, 3.82);
P = 1.2e06
441 2.12 (1.55, 2.91);
P = 2.4e06
rs10760130 657 484 750
One copy 309 1.23 (0.86, 1.78) 223 1.31 (0.86, 1.98) 367 1.63 (1.17, 2.29)
Two copies 143 1.58 (1.03, 2.44) 112 1.47 (0.89, 2.40) 161 1.22 (0.81, 1.84)
Carriage 1.33 (0.95, 1.86);
P = 0.10
1.36 (0.92, 2.00);
P = 0.12
1.50 (1.09, 2.05);
P = 0.01
rs2900180 658 485 753
One copy 300 1.54 (1.11, 2.15) 222 1.50 (1.02, 2.22) 353 1.58 (1.15, 2.15)
Two copies 87 1.25 (0.76, 2.03) 68 1.10 (0.63, 1.90) 105 1.37 (0.88, 2.15)
Carriage 1.47 (1.07, 2.02);
P = 0.02
1.40 (0.97, 2.00);
P = 0.08
1.53 (1.14, 2.05);
P = 0.005
The comparison group for anti-CCP: anti-CCP-negative patients. The comparison group for the SNP markers: patients who carry
two copies of the non-risk allele. Carriage: at least one copy of the risk allele i.e. dominant model. CCP: cyclic citrullinated peptide.
TABLE 3 Association between prognostic factors and Larsen score in patients with erosive disease
Marker
5-year IP
cohort obs.
Larsen score
at Year 5 IRR
(95% CI)
5-year RA
subgroup obs.
Larsen score
at Year 5 IRR
(95% CI)
1-year RA
cohort obs.
Larsen score
at Year 1 IRR
(95% CI)
Anti-CCP 228 214 265
Positive 127 1.57 (1.34, 1.84);
P = 5.9e8
126 1.51 (1.29, 1.78);
P = 1.5e6
168 1.24 (1.06, 1.45);
P = 0.009
HLA-SE 244 231 284
Carriage 1.24 (1.04, 1.47);
P = 0.02
1.21 (1.01, 1.45);
P = 0.04
1.18 (0.99, 1.41);
P = 0.06
rs10760130 262 245 297
One copy 126 0.97 (0.80, 1.17) 119 0.95 (0.79, 1.15) 158 1.00 (0.84, 1.20)
Two copies 68 0.98 (0.79, 1.22) 63 0.99 (0.80, 1.23) 59 1.00 (0.80, 1.24)
Carriage 0.97 (0.82, 1.16) 0.97 (0.81, 1.16) 1.00 (0.84, 1.18)
rs2900180 263 246 298 1.02 (0.87, 1.20)
One copy 136 0.95 (0.80, 1.13) 126 0.95 (0.80, 1.13) 153 0.92 (0.73, 1.17)
Two copies 36 1.03 (0.81, 1.33) 34 1.05 (0.82, 1.35) 41 1.00 (0.86, 1.17)
Carriage 0.97 (0.83, 1.14) 0.98 (0.83, 1.15)
The comparison group for anti-CCP: anti-CCP-negative patients. The comparison group for the SNP markers: patients who carry
two copies of the non-risk allele. Carriage: at least one copy of the risk allele i.e. dominant model. CCP: cyclic citrullinated peptide.
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be an important effect, illustrated by extensive overlap in
CIs between Years 1 and 5, and, in addition, the contrary
was observed for ACPA positivity (Table 2). For both
SNPs, carriage of one copy of the risk allele appeared
to confer a higher risk of erosions than carriage of two
copies when compared with carriage of no copies.
However, there were low numbers of patients with two
copies of either risk allele and a substantial overlap in
CIs was observed. None of the other SNP markers
tested showed association with erosions in this 1-year
RA cohort.
Multivariate analysis of genetic markers: ACPA status
Multivariate logistic regression models were used to
assess the improvement in predicting erosions in IP
patients who carried the risk allele of either rs10760130
or rs2900180, over and above that estimated from ACPA
positivity alone. In the 5-year IP cohort, carriage of the risk
allele for either rs2900180 [n = 572; OR 1.65 (95% CI 1.13,
2.42); P = 0.01] or rs10760130 [n = 571; OR 1.52 (95% CI
1.00, 2.29); P = 0.05] conferred risk of erosions in IP
patients following adjustment for ACPA positivity, and
effect sizes were similar in the ACPA-negative patients
[n = 404; OR 1.52 (95% CI 0.98, 2.38); P = 0.06] and
[n = 403; OR 1.42 (95% CI 0.88, 2.29); P = 0.15] were
compared with the ACPA-positive subgroup [n = 168; OR
2.07 (95% CI 0.97, 4.40); P = 0.06] and [n = 168; OR 1.80
(95% CI 0.82, 3.90); P = 0.14] for rs2900180 and
rs10760130, respectively (difference in effect between
patient stratum P = 0.50 for rs2900180 and P = 0.62 for
rs10760130).
Following adjustment for ACPA positivity, carriage of
the risk allele of rs10760130 also predicted erosive dis-
ease in the 1-year IP cohort [n = 672; OR 1.62 (95% CI
1.13, 2.33); P = 0.009]. Importantly, carriage of the minor
allele conferred risk of erosions in ACPA-negative patients
[n = 407; OR 2.30 (95% CI 1.39, 3.80); P = 0.001], but not in
ACPA-positive patients [n = 265; OR 1.00 (95% CI 0.56,
1.79); P = 0.99] and this difference was significant
(P = 0.03). The result was corroborated by receiver
operating characteristic analysis in which inclusion of
rs10760130 did not improve the diagnostic utility of
ACPA positivity (analysis not shown). Similarly, carriage
of the risk allele for rs2900180 was predictive of erosions
at Year 1 following adjustment for ACPA positivity
[n = 675; OR 1.48 (95% CI 1.06, 2.08); P = 0.02] and con-
ferred risk of erosions in ACPA-negative patients [n = 408;
OR 1.71 (95% CI 1.11, 2.65); P = 0.02], but not ACPA-
positive patients [n = 267; OR 1.18 (95%CI 0.68, 2.04);
P = 0.6]. The difference was not significant (P = 0.3). Both
rs2900180 and rs10760130 were investigated in the con-
text of HLA-SE carriage to see if a statistical interaction
between the genetic loci existed; however, none was
detected (data not shown).
Discussion
Recent large-scale whole-genome and candidate gene
association studies have identified a number of SNP
markers that reproducibly associate with RA susceptibil-
ity, substantially improving our understanding of the
genetic component of disease susceptibility. While this
is important, it is unlikely to have an immediate clinical
impact unless these markers also associate with progno-
sis or treatment response.
We hypothesized that genetic susceptibility markers
may also be important predictors of outcome. In the cur-
rent study, the SNP markers rs10760130 and rs2900180
(TRAF1/C5) were associated with erosive disease
(Table 2), but not with higher Larsen scores at either
Year 1 or Year 5 in patients with erosive disease (i.e.
Larsen score of 52 in at least one joint; Table 3). In con-
trast, ACPA positivity and carriage of HLA-SE were asso-
ciated with the presence of erosions, Larsen score and
with the number of eroded joints (data not shown). This
suggests that, unlike ACPA status and carriage of
HLA-SE, the TRAF1/C5 locus may predict those patients
who are more likely to develop erosive disease, but not
the severity or extent of erosions. It should be noted that
in this investigation, 18 SNPs mapping to 14 loci were
assessed for association with disease outcome resulting
in multiple testing and the consequent potential of gener-
ating false positive results. No correction has been
applied, so as not to preclude the identification of small
putative effects, but, if it had, neither of the SNP markers
would have achieved statistical significance at the cor-
rected threshold (P< 0.003). However, the association of
the TRAF1/C5 locus with erosive disease has previously
been reported (with the SNP rs10818488; in R2= 1 with
rs10760130) [25]. Hence, the current findings provide fur-
ther support that this locus is associated with disease
outcome. In the current study, the effect seen at the
rs2900180 SNP locus in patients homozygous for the
risk allele was observed to be lower than that observed
for heterozygotes, albeit with considerable overlap in the
CIs. Although the effect at this locus is consistent with a
dominant model, this pattern perhaps reflects the small
number of observations in the homozygous patient
group (Table 2). However, validation of association of
the locus with disease severity is required in larger, inde-
pendent data sets.
Logistic regression analyses found that the TRAF1/C5
genetic markers (rs10760130 and rs2900180) predict
erosive disease independent of ACPA status; indeed,
the effect appears stronger in ACPA-negative patients at
Year 1. This could be more helpful clinically as this
subgroup is often not treated as intensively as ACPA-
positive patients. The presence of genetic risk alleles
may highlight the potential for erosive damage and
prompt clinicians to consider earlier, more aggressive
treatment regimes. The sensitivity (80% for rs10760130
and 66% for rs2900180) and specificity (36% for
rs10760130 and 46% for rs2900180) of genotyping at
either locus, in ACPA-negative patients, to predict the
development of erosions by Year 1 is too low to be clin-
ically useful at the current time but, as more markers of
severity are identified, this may become viable in the
future.
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Failure to detect associations with the other suscepti-
bility loci tested may reflect inadequate power. Assuming
a 50% increase in risk of developing erosions, the study
had 14–95% power to detect the effect of carriage of a
susceptibility allele at eight of the loci tested [rs5029937
(14%), rs6822844 (64%), rs4750316 (80%), rs7574865
(88%), rs4810485 (90%), rs6920220 (91%), rs13207033
(94%) and rs6897932 (95%)] at Year 5 in IP patients, at
the 5% significance level. There was >95% power for the
remaining loci. The study therefore had limited power to
detect modest effects due to the limited sample size, par-
ticularly for some of the subgroups analysed and may,
therefore, represent false negative findings. For many of
these regions, either multiple polymorphisms have been
associated with susceptibility and/or the true causal vari-
ants have not yet been identified resulting in a further loss
in power to identify potential modest severity effects.
National and international collaboration is likely to be
required to establish large enough cohorts to fully explore
genetic predictors of outcome. Alternatively, genetic sus-
ceptibility markers may differ from those contributing to
disease severity. If this is true, there is a need for a sep-
arate well-powered within-cohort genome-wide associa-
tion study to identify genetic markers of outcome and to
improve the predictive models over and above the pres-
ence of ACPA positivity alone.
These data add more weight to the case for routine
screening for ACPA in clinical practice in order to identify
those patients who are likely to have a poor prognosis in
terms of radiographic erosions. These data also add to the
evidence that SNP markers within the TRAF1/C5 locus are
associated with the risk of erosive disease and suggest
that this effect is independent of ACPA.
Rheumatology key messages
. ACPA positivity remains the strongest predictor of
radiological outcome in patients with IP.
. We provide evidence that the TRAF1/C5 locus is
associated with erosive disease in IP patients.
. The TRAF1/C5 locus is associated with excess risk
of erosive disease independent of ACPA status.
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